June 17 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc VRX.TO
* Valeant Pharmaceuticals announces significant investments
in Canadian operations
* $12.5 million investment in Laval, Quebec facility and
transfer of Arestin production
* $15 million investment in Steinbach, Manitoba facility and
transfer of Xifaxan and Apriso production
* Valeant Canada expanding Canadian manufacturing, export
capacity with investments totaling $27.5 million
* $15 million investment includes $7 million in upgrades to
product manufacturing technology
* $15 million investment also includes $8 million for
transfer of North American production of Xifaxan (rifaximin) and
Apriso
Source text for Eikon: ID:nCNW2mjTda
Further company coverage: VRX.TO